You are here

  • Home
  • Archive
  • Volume 9, Issue 3
  • External validation of the 2022 ACR/EULAR classification criteria in patients with suspected giant cell arteritis in a Dutch fast-track clinic

Article info

Article menu

Download PDFPDF

Vasculitis
Original research
External validation of the 2022 ACR/EULAR classification criteria in patients with suspected giant cell arteritis in a Dutch fast-track clinic

Authors

  • Marieke van Nieuwland Department of Rheumatology and Clinical Immunology, Ziekenhuisgroep Twente (Hospital Group Twente), Almelo, The NetherlandsDepartment of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands PubMed articlesGoogle scholar articles
  • Lenny van Bon Department of Rheumatology and Clinical Immunology, Ziekenhuisgroep Twente (Hospital Group Twente), Almelo, The Netherlands PubMed articlesGoogle scholar articles
  • Marloes Vermeer ZGT Academy, Ziekenhuisgroep Twente (Hospital Group Twente), Almelo, The Netherlands PubMed articlesGoogle scholar articles
  • Elisabeth Brouwer Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands PubMed articlesGoogle scholar articles
  • Celina Alves Department of Rheumatology and Clinical Immunology, Ziekenhuisgroep Twente (Hospital Group Twente), Almelo, The Netherlands PubMed articlesGoogle scholar articles
  1. Correspondence to Marieke van Nieuwland; m.vnieuwland{at}zgt.nl
View Full Text

Citation

van Nieuwland M, van Bon L, Vermeer M, et al
External validation of the 2022 ACR/EULAR classification criteria in patients with suspected giant cell arteritis in a Dutch fast-track clinic
RMD Open 2023;9:e003080. doi: 10.1136/rmdopen-2023-003080

Publication history

  • Received February 23, 2023
  • Accepted June 25, 2023
  • First published July 28, 2023.
Online issue publication 
July 28, 2023

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.